GCI-based Host Defense Modifiers

About Sidanis Pharma

Sidanis Pharma is a private, pre-clinical stage biotech company pioneering a novel class of drugs called glycoconjugate immunostimulators (GCI). These molecules are designed to selectively activate the mammalian immune system, either as vaccine adjuvants or as broad-spectrum host defense modifiers, to combat infectious diseases. The company's mission is to address the global threat of antimicrobial resistance by providing alternatives or supplements to traditional antibiotics and vaccines. Operating from Berlin, Sidanis is positioned in the high-growth infectious disease therapeutics market with a platform technology that could represent a paradigm shift in infection control.

Therapeutic Areas